Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis Report 2017 - Shire, BioCryst Pharma and Ionis Pharma are Dominating -

Research and Markets
Posted on: 07 Mar 18

The "Hereditary Angioedema (HAE) Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to's offering.

The study analyzed that HAE therapeutics pipeline comprises 20 drug candidates in different stages of development.

According to research findings, most of the drug candidates of the HAE are being derived from the natural sources. The natural sources consist of various molecules such as gene therapies, biologicals, and RNA.

Most of the companies have developed novel technologies for the development of drug candidates for the treatment of HAE. For instance, Arrowhead Pharmaceuticals, Inc. has established a drug discovery, and development platform that has broad licenses to fundamental intellectual property and extensive scientific expertise after more than a decade working on RNAi-based therapies. These technologically advanced platforms enable the players in the pipeline to develop effective new therapies rapidly, that are cost effective and potentially have lower risk, relative to traditional approaches. These technological advancements act as a key driver for pipeline growth.

The positive clinical results of HAE drug candidates are driving the pipeline growth. For instance, Attune Pharmaceuticals, Inc., announced the Pre-Clinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. Studies demonstrated that ATN-249 was highly selective and potent at plasma kallikrein inhibition in both biochemical inhibition and contact activation assays. Therefore, the positive clinical results of the compounds under the development for the treatment of HAE, are fueling the research and development investment being made by the players developing drugs for the treatment of HAE.

Some of the key players developing drugs for the treatment of HAE therapeutics include Shire plc, BioCryst Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

Chapter 5. Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis by Phase (2017)

5.1 Phase III: Drug profiles

5.2 Phase II: Drug profiles

5.3 Phase I: Drug profiles

5.4 Pre-Clinical: Drug profiles

5.5 Discovery: Drug profiles

Chapter 6. Clinical Trials Analysis

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Hereditary Angioedema (HAE) Therapeutics Pipeline

7.2 SWOT Analysis of Hereditary Angioedema (HAE) Therapeutics Pipeline

Chapter 8. Company Profiles

  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Shire PLC

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.